Amendment No. 1 to LICENSE AGREEMENTLicense Agreement • April 1st, 2024 • Omeros Corp • Pharmaceutical preparations
This Amendment No. 1 to License Agreement (this “Amendment No. 1”) is made effective the 5th day of January 2011 (the “Effective Date”) between Daiichi Sankyo Company, Limited, a Japanese Corporation having a place of business at 5-1, Nihonbashi Honcho 3-Chome, Chuo-ku, Tokyo 103-8426 Japan (“DS”), and Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, WA 98101 USA (“Omeros”).
LICENSE AGREEMENT between ASUBIO PHARMA CO., LTD. and OMEROS CORPORATIONLicense Agreement • April 1st, 2024 • Omeros Corp • Pharmaceutical preparations • New York
This license agreement (this “Agreement”) is made effective the 3rd day of March 2010 (the “Effective Date”) between Asubio Pharma Co., Ltd., a Japanese Corporation having a place of business at 9-11 Akasaka 2-Chome, Minato-Ku, Tokyo 107-8541 Japan (“Asubio”), and Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, WA 98101 USA (“Omeros”).
Amendment No. 2 to LICENSE AGREEMENTLicense Agreement • April 1st, 2024 • Omeros Corp • Pharmaceutical preparations
This Amendment No. 2 to License Agreement (this “Amendment No. 2”) is made effective the 25 day of January 2013 (the “Effective Date”) between Daiichi Sankyo Company, Limited, a Japanese Corporation having a place of business at 5-1, Nihonbashi Honcho 3-Chome, Chuo-ku, Tokyo 103-8426 Japan (“DS”), and Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, WA 98101 USA (“Omeros”).
AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT BETWEEN OMEROS CORPORATION AND DRI HEALTHCARE ACQUISITIONS LP Dated as of February 1, 2024Royalty Purchase Agreement • April 1st, 2024 • Omeros Corp • Pharmaceutical preparations • New York
This Amended and Restated Royalty Purchase Agreement (this “Agreement”), dated as of February 1, 2024, between Omeros Corporation, a Washington corporation (“Seller”), and DRI Healthcare Acquisitions LP, a Delaware limited partnership (“Purchaser”) (each, a “Party” and together, the “Parties”), amends and restates in its entirety that certain Royalty Purchase Agreement (the “2022 Royalty Purchase Agreement”), dated as of September 30, 2022 (the “2022 Effective Date”), between Seller and Purchaser.
